COX-2 inhibitors associated with blood pressure...( CHICAGO An analysis of 19 randomized c...),Health

CHICAGO An analysis of 19 randomized controlled trials involving COX-2 inhibitors (selective cyclooxygenase-2 inhibitors) suggests that these agents raise blood pressure more than either conventional nonsteroidal anti-inflammatory drugs (NSAIDs) or placebo, according to a study to be published in an upcoming issue of The Archives of Internal Medicine, one of the JAMA/Archives journals. The study is posted online today because of its relevance to current events surrounding this class of drugs. It will be published in a future print edition of the journal.

NSAIDs, among the most widely prescribed drugs for pain relief, are associated with gastrointestinal side effects. As a result there has been a significant preference to prescribe COX-2 inhibitors over conventional NSAIDs, even when patients do not meet specified criteria for treatment, according to background information in the article. Some COX-2 inhibitors have been associated with an increased risk of cardiovascular events.

Tai-Juan Aw, M.B.B.S., F.R.A.C.P., Monash University, Melbourne, Australia, and colleagues, analyzed data from all 19 randomized controlled trials of COX-2 inhibitors published before May 2004, with a total of 45,451 participants for whom blood pressure data were available. The meta-analysis was designed to compare the relative risk of developing hypertension and of clinically important blood pressure elevation in study participants treated with COX-2 inhibitors versus those treated with NSAIDs or placebo.

COX-2 inhibitors were associated with a blood pressure elevation compared with NSAIDs and placebos, the authors found. These blood pressure elevations may be clinically significant in relation to increased cardiovascular risk. The authors also saw differences between the COX-2 inhibitors. "Rofecoxib appears to confer a greater risk of developing hypertension and clinically important elevations in both systolic and diastolic blood pressure compared with cele
'"/>

Contact: Henry Krum, M.B.B.S, Ph.D.
Henry.Krum@med.monash.edu.au
JAMA and Archives Journals
14-Feb-2005

Page: 1 2
Related medicine news :

1. COX-2 product offers good and bad news in test tube strokes
2. COX-2 inhibitor increases the risk of heart attack in elderly adults with no history of heart attack
3. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
4. Special JAMA commentary on lessons learned from troubles with COX-2 inhibitors
5. NIH halts use of COX-2 inhibitor in large cancer prevention trial
6. Estrogen-associated COX-2 pathways explain protection from heart disease in female mice
7. COX-2 inhibitor could be safest anti-inflammatory drug for older people
8. Lupus discovery may pave way to better-designed COX-2 inhibitors
9. Study findings question COX-2 drug cost effectiveness
10. COX-2 inhibitors and the elderly
11. Aspirins target, the COX-2 enzyme, linked to cancer of the uterus